Showing posts with label Memorial Sloan Kettering. Show all posts
Showing posts with label Memorial Sloan Kettering. Show all posts

Monday, January 28, 2019

The complicated news from MSK as of the end of January 2019

The prologue:   

MSK gave me a prognosis for the first time, when we met with our oncologist on Thursday, January 24, 2019. The prognosis is six months.

The reasons:

I had been having difficulties. A scan back on December 11, 2018 had determined that my cancer was again in action. Shaping a response to that took time, both because of the holiday season and because I’m sure the doctors wanted to be as careful as possible. The conclusion they seemed to be coming to, even before we met on January 24, was that there were no good affirmative treatments likely to be available. We had no doubt this was a reasonable assessment of the situation, but felt that it might still be true that even a treatment unlikely to succeed was better than no treatment at all. Our oncologist’s view was, we thought, evolving to the opposite perspective: that if no treatment was likely to be successful then there was no point in trying them at all.

What decided the issue was a series of scans in late January, which included a January 15 X-ray of my abdomen as well as a CT scan, that same day, of my abdomen and pelvis done during my digestive blockage visit to MSK’s Urgent Care ward (a visit I blogged about as well). They also included an MRI of my pelvis on January 22. I had yet another scan on January 25, but that was to diagnose whether I had suffered a broken foot or not, and didn’t otherwise contribute to the study of my condition.

In truth, the information in theses scans is hard to keep clear and distinct. One scan is referred to as comparing its findings with data from a scan done a couple of days later, but I had no such additional scan that day. Another scan attributes the wrong disease to me – saying I have colon cancer when I actually have a different illness, cholangiocarcinoma. These mistakes are a bit unsettling, but the general import of the scan results nevertheless emerges clearly.

If the scans proved determinative, what led MSK to determine that they should do the scans in the first place? Their concerns were triggered in good part by the MSK physicians’ growing suspicion about a lesion, a damaged area, in my right iliac bone, which is part of the pelvis. MSK had been aware of this spot since approximately April 2018, but had not been particularly suspicious about it. Now, however, yet another scan in December 2018 had shown growth in this spot, and growth is important. For our part, we too had hoped not to need to pay attention to this spot. After all, I didn’t think I had any symptoms of it at all – but over the weekend before the scan I began to realize that maybe I did have symptoms, perhaps from walking further than was comfortable, perhaps from such minor motions as bending over to do the dishes. Mostly not a lot of pain – but cholangiocarcinoma is full of minor, yet ultimately meaningful, symptoms. Meanwhile, growth is cancer’s specialty, so the fact that this spot had recently started to grow was a bad sign.

The scan series in January 2019 appears to have confirmed two thoughts for our oncologist. The first is that the cancer has escaped from the liver and reached the bones as well. One report, on still another CT scan done on January 15, 2019, indicated this but not elaborately; a second, on an MRI scan done a week later, January 22, 2019, left no room for doubt. There has been a lot of damage to the bones of the pelvic area, presumably the result of its infiltration by the cancer, and all of it appears to have taken place in the last 12 months. Parts of the bone have probably died. All of this makes me vulnerable to things like bone fractures, including hip fractures, which would put me right away in a wheelchair.  

When the skeleton weakens, you are at greater risk both for “spontaneous” fractures, which can apparently take place while you’re doing nothing more strenuous than sleeping, and for fractures caused by impact and accident. There are things that can be done to reduce the chances of incident, such as installing assistive equipment, like guide bars, machinery to help me get around the house; as we do more with this I may blog about our progress, but in any case this effort is now underway.

As to the impact and accident fractures, for me those are more likely than they otherwise might be because of all the water I’m still retaining, especially in my feet. The water retention is another impact of my damaged liver (and of its interaction with the diuretic medication, and in turn with my kidneys). The water retention in itself isn’t a big problem, and doesn’t contribute to my underlying cancer in any direct way. However, in the Department of Irony, currently running strong, a couple of hours after we got home from our Thursday meeting last week with the oncologist, at which we’d received a lot of precautionary guidance, I fell at the bottom of our stairs. Fortunately the fall was only two steps down. I landed hard, but even more fortunately the fall didn’t fracture anything; it caused “just” a sprain. My left foot did take on some remarkable colors right away. Depending on how many separate sprains I gave myself, recovery could take as long as six or seven weeks. So far, however, things seem to be moving quite quickly and positively.

The second conclusion our oncologist and her colleagues have reached is that my liver has already been seriously damaged. One measure of such damage is the growth of the cancer itself, and the January 15 CT scan of my abdomen and pelvis lists a number of growing, and probably new, changes in my liver and bile duct of this sort. Other evidence comes from blood testing of liver function. My general sense is that my liver and kidney blood numbers were good until the conclusion of the high-intensity radiation treatment this past summer, and that at that point they began to deteriorate. It’s easy to see what caused the damage: not the water retention, but rather the combination of three years of different powerful treatments, including chemotherapy and, most recently, high-intensity radiation. These all did their job, staving off or pushing back the cancer for years – the oncologist has been happy to have me as an “outlier” to the normal course of the disease – but the price was liver damage. I’ve recently read that actually the liver handled over 500 different functions in the body, not just the 400 I’d seen referred to earlier. Any of those may now be malfunctioning.

What’s bad about liver damage is that there is no cure for it. It is possible for the liver to regenerate, but that is a slow process and one under nature’s guidance; there seems to be little if anything a doctor can do to bring about regeneration by direct medical intervention. There is no “liver-all” pill to take 3 times a day! The only method available to doctors of which I’m aware is resection – the complete surgical removal of part of the liver, but MSK has never seen me as a good candidate for this approach. That means that any heavy-duty treatment that gets applied at this point runs the risk of deepening my current liver problems, and if the liver stops functioning, that is really the end.

What is to be done next?

That in turn suggests that what’s ideal for me is to stick with exactly what I now have. The status quo has its inconveniences, such as water retention, but they can all be managed. Evidently, however, our oncologist anticipates a continued deterioration of the liver, presumably as a result of a continued growth of my cancer.

To stave that off as long as possible therefore becomes our next goal. Happily, there is something that can be done about this: the application of low-intensity radiation. High-intensity beams are too powerful and too dangerous, but low-intensity beams have been in use for a number of years and their capacity to slow, though not end, expansion of the cancer in the bones (and perhaps even in the liver itself – a point I want to ask more about) is evidently well-established.

One other point: I exaggerated a bit when I said that MSK took the view that there was nothing truly affirmative to be done. There is one treatment available which, though not very promising for patients with my kind of cancer (it wasn’t designed with this illness in mind), still could conceivably help and even help a lot: Keytruda. This is the drug that helped Jimmy Carter fight off brain cancer. MSK is comfortable with trying it because they feel they know very well what its potential downsides in the body are, and they’re mild. So they are quite confident that Keytruda won’t undermine what’s left of my liver functioning, and though it likely won’t improve matters either, it will succeed or fail without further weakening me.

The only problem with Keytruda is that it is very expensive – I think over $10,000 for each treatment, with the treatments every three weeks. Merck, which makes Keytruda, enables many potential patients to get around this problem by giving them access to the drug as a “compassionate use” under federal law; no doubt this is only partly an act of charity, while also serving as a way for Merck to continue gathering data on its drug, with a view to the widest possible use and sale of the medication. In any case, we and MSK have applied to receive the drug as a compassionate use. Decisionmaking at Merck this month has apparently been slow, for reasons no one outside the company is sure of, but we will continue to press the point.

There may be other possibilities, though with the difficulties my liver and kidneys now face I may not easily be able to qualify for most experimental trials. Even if I can qualify, we’ll have to determine whether these experiments make sense for me. For example, we’ve certainly considered the “CAR-T” experiment at the National Institutes of Health, a trial in which the patient’s immune system is more or less entirely removed, re-trained to focus on cholangiocarcinoma, and then returned to the patient’s body. The general sense Teresa and I have is that steps like these are a last resort, or no resort at all, because they do pose serious risks of danger to the patient – especially, we assume, one with a damaged liver already.

And meanwhile:

I plan to live the life I’ve lived, valuing and spending time with my family and friends. I also plan to continue the final steps in the work that I’ve had underway, the biography of my late South African friend Arthur Chaskalson, roughly since I received my diagnosis in 2015. I’ve often felt since I became ill that each day in itself is a wonderful thing. In recent months my sense of this has wobbled at times, so now I mean to remind myself, and to take joy in each remaining day. And if there turn out to be a lot of those remaining days, so much the better!

                                                                                                                 

Friday, December 14, 2018

Latest news -- back to the fight


Teresa and I spent yesterday at Memorial Sloan Kettering. Unfortunately we didn't come home with news as good as we had gotten from other recent sessions there.

The short version is this: they found from a CT scan on Tuesday, December 11, 2018 that a few tumors in my liver which had been quiet have now woken up and grown a little (roughly a centimeter in each case). Meanwhile a very small lesion in my iliac bone (a “lesion” is a damaged area, and the iliac is the largest bone of the pelvis), which they’ve been aware of but have never seen any clear indication of malignancy from, has also grown a little, which raises a substantial possibility that this is a metastasis (a spread) outside the liver.

What to do? Well, we intend to fight the disease, which is the strategy that has served us pretty well up to now. But it’s harder, because we’ve already used most or all of the proven strategies. (Though perhaps not all; we may talk with the doctor who administered the radiation this summer, for instance, in case he sees something our oncologist – who was out during our appointment yesterday with a respiratory illness, so we only really dealt with her nurses – did not.) Assuming we’ve tried everything proven that Sloan Kettering offers, we might actually sit tight, not getting treatment. This would not be because we’re giving up, but rather because if the tumors in question are growing relatively slowly, then for my case (somewhat as in many cases of men with prostate cancer) it can actually make sense to be equally patient – while we wait for researchers and clinicians to invent the next treatment that really works.

Or we may try experimental treatment ourselves. Experiments, in the form of clinical trials, are the process by which those treatments that really work are found and developed. Getting a treatment that is currently unproven won't accomplish much if it turns out the treatment really doesn't work. But joining the trial means that you potentially get access to the latest possible approaches earlier than other people do, and if they work you get your treatment before most of the world. 

One especially attractive example of this would be the drug Keytruda, which you might remember successfully pushed back Jimmy Carter’s brain cancer. Keytruda is an immunotherapy drug, and it helps to have the right mutations for Keytruda and other similar immunotherapy drugs to target. So far it doesn’t seem that I have any particularly “targetable” or “actionable” mutations. But some people benefit from these drugs even without having the mutations at which they were originally aimed. The biggest problem with Keytruda, aside from the fact that it certainly doesn’t always work, is that it is expensive, unless they (Merck is the manufacturer) give it to you as a compassionate gesture. That they often do, and we applied for it yesterday.

A second place for experimental treatment is in other treatments being tried inside Sloan Kettering itself. MSK evidently has two sets of first-round (i.e. very tentative) clinical trials going on. One set involves immunotherapy (that is, treatment aimed -- like Keytruda -- at the targetable mutations that I seem to be short of, but that perhaps aren’t essential to the success of treatment). The second set involves, I guess, other  experiments. It looks like we’ll be finding out more about these in the next two or three weeks.

The third place for experimental treatment is, as you’d guess, in other treatments besides Keytruda that are being developed outside Sloan Kettering. Different institutions are running their own trials. There’s a possibly promising one at M.D. Anderson in Houston; another at the National Institutes of Health in DC; and Teresa is applying her formidable web research skills to locating others that show some promise.  

So that’s the situation. I intend to work hard on finishing the 400,000 word version of my book (and if I can also produce a shorter version, more suitable for trade publication, so much the better); look forward to spending time with family and friends; and, as I said, Teresa and I plan to keep on fighting.  

Sunday, November 25, 2018

Three years in and still going strong

Today, November 25, is the third anniversary of my receiving the diagnosis of cholangiocarcinoma. The actual diagnosis was not the first sign that I had cancer; in fact, tests had already made that clear. But the last round of testing convinced the doctors that the particular kind of cancer I had was bile duct cancer, a/k/a cholangiocarcinoma, and that’s what I’ve been treated for ever since.

And here I am, three years in and still going strong. The doctors believe that the radiation treatment I had this summer either killed or knocked out of action all my remaining tumors. Based on that, my oncologist told us this month that she was completely comfortable with my not having another scan until January – and that in turn points to her feeling that there would be nothing for a scan to find. Hopefully the scan in January will confirm this, and that would be really good news. But if what it shows is that something has returned, and if that something can in turn be hit by another round of radiation, that will be good too. 

The only downside, which I’ve written about already, is the side effects. I’ve got several, none terrible but all a bit of a bother. I’m tired a lot, and my energy for things like a regular daily walk has declined, as has my walking speed. I’m retaining water, though fortunately not too much; to deal with this, however, requires medicine that in turn can affect other parts of me (basically, the balance seems to be between my liver and my kidneys), so the doctors are doing their best to give me just the right amounts. And the side-effect that may puzzle the doctors the most is that I have cramping in my hands and legs. This one doesn’t seem to have a single cause; it’s evidence, I think, that the body is a complex apparatus and multiple factors can coincide in a particular effect, happily again not that severe. But the odd result of all this is that although fundamentally I’m clearly healthier – no active cancer! There’s a result I didn’t count on three years ago – in these various more superficial ways I don’t feel that great. 

All that said, however, here I am. Last night I woke up at 4 AM feeling nauseous, but a single pill did the job on that symptom. And today Teresa has spent making meat pies (with the inspiration of the British Bake Off show, which we both have been watching), and we will try these home made meat pies tonight. (We had one and it was great!) It is good to be here to get to sample this pleasure. 

While not eating pie or taking a nap to catch up on my sleep I’ve also been making revisions to my book; there is always more to do, and I’m still involved in complex dealings with potential publishers, but today I completed one set of reader’s comments, and so this day marked a writing milestone too. I hope the book will actually be published around mid-2019. If and when that’s done then I will face the interesting question of what to do next. One particularly intriguing possibility is that I write manuals for cholangiocarcinoma patients on the law governing their health insurance, a topic that turns out to have many pitfalls which can confuse a lawyer, e.g. me, and no doubt frustrate a non-lawyer even more completely. Or, of course, there’s the possibility of a European river cruise. Or other places to travel and books to read. I’m looking forward to the chance to choose. The world has so much going on in it! 

Sunday, September 23, 2018

Another Footnote, This One Ironic




On September 12 I wrote about the failure by a senior MSK doctor to disclose his financial interests in connection with many of the articles that he was publishing. That story in the NY Times was quickly followed by another, about this doctor resigning from his job. That was perhaps predictable. It was less predictable that a new scandal at MSK would be unearthed just a couple of days later, though I did have the feeling the story hadn’t yet been told in full. 

In fact I still have that feeling, and wonder what investigations are now underway at MSK’s competitor institutions. It strikes me as unlikely that only MSK has been infected by the kinds of maneuvers that these articles reveal. After all, these maneuvers are presumably profitable, directly or indirectly, and health care institutions must be competing with each other to provide the best possible pay packages to their top employees. (They certainly are competing with each other to attract patients, as medical advertisements and hospital merger news attest.)

In any case, on September 20 it was revealed that senior MSK doctors or scientists and some board members, along with MSK itself, were the co-owners of an artificial intelligence start-up meant to use MSK’s immense library of accumulated tissue samples to learn better how to diagnose the presence of cancer. In the process, it appears, the people involved disregarded rules governing such "related party" dealing (which is not illegal in itself, but must be correctly structured). They annoyed other MSK physicians by using the results of those doctors’ research in analyzing the tissue samples without their consent. And  this venture turned the samples donated by patients towards the goal of research into potential sources of private profit that surely were never consciously consented to.

I don’t want to say that the issues posed by the duties of honesty, disclosure and frankness are always simple, as my earlier post on nondisclosure may have implied. Truth isn't always the commanding rule -- but it is an important rule, as the age of Trump underlines. Here, it appears that MSK could not get venture capital funding for a project it believed was very promising, and so the investors – as investors tend to do – took on some special risk in the hope of some special gain. That gain in turn would have benefited us. 

But at the same time this series of stories gives the impression that our major medical institutions have decided that the way to provide care is to find profit to support it, and that the task of finding sources of profit need not be undertaken with any over-punctilious concern for virtues like disclosure. What’s perhaps most troubling about the creation of such a culture of gain is that it undercuts the culture of cure that so many of the staff at institutions like MSK pursue with daily dedication -- including in my own case.